Awareness of the metabolic syndrome in patients with bipolar disorder

A comparison of US and European psychiatrists

Yves Lecrubier, Michael Bauer, Robert Hirschfeld, Susan Mcelroy, Trisha Suppes

Research output: Contribution to journalArticle

Abstract

Introduction. The metabolic syndrome is a relatively new concept still being debated in the US and Europe; little is known about how it is factored into psychiatric treatment decisions. Method. Practicing psychiatrists in the US (n=500) and five European countries (UK, France, Italy, Germany, Spain; n=718) participated in brief online surveys in 2005 and 2006. Results. US psychiatrists were more likely than EU psychiatrists surveyed to view metabolic syndrome as a significant health risk; US respondents reported significantly more bipolar patients who were overweight or obese, but similar percentages of bipolar patients who met criteria for the metabolic syndrome. More US than EU psychiatrists reported monitoring metabolic parameters before and during treatment, and generally were more concerned about bipolar medication adverse effects (AEs). Significantly more US psychiatrists indicated that they were extremely or very concerned about weight gain as an AE. Conclusions. For most surveyed US and EU psychiatrists, metabolic health is an important concern in the treatment of bipolar disorder. US psychiatrists reported more often monitoring metabolic parameters and adjusting treatment if abnormalities become evident, but practices are evolving in the US and EU.

Original languageEnglish (US)
Pages (from-to)187-195
Number of pages9
JournalInternational Journal of Psychiatry in Clinical Practice
Volume12
Issue number3
DOIs
StatePublished - 2008

Fingerprint

Bipolar Disorder
Psychiatry
Health
Therapeutics
Spain
Italy
Weight Gain
France
Germany

Keywords

  • Bipolar disorder
  • Cardiovascular diseases
  • Metabolic syndrome X
  • Obesity
  • Weight gain

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Awareness of the metabolic syndrome in patients with bipolar disorder : A comparison of US and European psychiatrists. / Lecrubier, Yves; Bauer, Michael; Hirschfeld, Robert; Mcelroy, Susan; Suppes, Trisha.

In: International Journal of Psychiatry in Clinical Practice, Vol. 12, No. 3, 2008, p. 187-195.

Research output: Contribution to journalArticle

Lecrubier, Yves ; Bauer, Michael ; Hirschfeld, Robert ; Mcelroy, Susan ; Suppes, Trisha. / Awareness of the metabolic syndrome in patients with bipolar disorder : A comparison of US and European psychiatrists. In: International Journal of Psychiatry in Clinical Practice. 2008 ; Vol. 12, No. 3. pp. 187-195.
@article{6da6544ea46946d6aa9bb5e07dfeae43,
title = "Awareness of the metabolic syndrome in patients with bipolar disorder: A comparison of US and European psychiatrists",
abstract = "Introduction. The metabolic syndrome is a relatively new concept still being debated in the US and Europe; little is known about how it is factored into psychiatric treatment decisions. Method. Practicing psychiatrists in the US (n=500) and five European countries (UK, France, Italy, Germany, Spain; n=718) participated in brief online surveys in 2005 and 2006. Results. US psychiatrists were more likely than EU psychiatrists surveyed to view metabolic syndrome as a significant health risk; US respondents reported significantly more bipolar patients who were overweight or obese, but similar percentages of bipolar patients who met criteria for the metabolic syndrome. More US than EU psychiatrists reported monitoring metabolic parameters before and during treatment, and generally were more concerned about bipolar medication adverse effects (AEs). Significantly more US psychiatrists indicated that they were extremely or very concerned about weight gain as an AE. Conclusions. For most surveyed US and EU psychiatrists, metabolic health is an important concern in the treatment of bipolar disorder. US psychiatrists reported more often monitoring metabolic parameters and adjusting treatment if abnormalities become evident, but practices are evolving in the US and EU.",
keywords = "Bipolar disorder, Cardiovascular diseases, Metabolic syndrome X, Obesity, Weight gain",
author = "Yves Lecrubier and Michael Bauer and Robert Hirschfeld and Susan Mcelroy and Trisha Suppes",
year = "2008",
doi = "10.1080/13651500701827671",
language = "English (US)",
volume = "12",
pages = "187--195",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Awareness of the metabolic syndrome in patients with bipolar disorder

T2 - A comparison of US and European psychiatrists

AU - Lecrubier, Yves

AU - Bauer, Michael

AU - Hirschfeld, Robert

AU - Mcelroy, Susan

AU - Suppes, Trisha

PY - 2008

Y1 - 2008

N2 - Introduction. The metabolic syndrome is a relatively new concept still being debated in the US and Europe; little is known about how it is factored into psychiatric treatment decisions. Method. Practicing psychiatrists in the US (n=500) and five European countries (UK, France, Italy, Germany, Spain; n=718) participated in brief online surveys in 2005 and 2006. Results. US psychiatrists were more likely than EU psychiatrists surveyed to view metabolic syndrome as a significant health risk; US respondents reported significantly more bipolar patients who were overweight or obese, but similar percentages of bipolar patients who met criteria for the metabolic syndrome. More US than EU psychiatrists reported monitoring metabolic parameters before and during treatment, and generally were more concerned about bipolar medication adverse effects (AEs). Significantly more US psychiatrists indicated that they were extremely or very concerned about weight gain as an AE. Conclusions. For most surveyed US and EU psychiatrists, metabolic health is an important concern in the treatment of bipolar disorder. US psychiatrists reported more often monitoring metabolic parameters and adjusting treatment if abnormalities become evident, but practices are evolving in the US and EU.

AB - Introduction. The metabolic syndrome is a relatively new concept still being debated in the US and Europe; little is known about how it is factored into psychiatric treatment decisions. Method. Practicing psychiatrists in the US (n=500) and five European countries (UK, France, Italy, Germany, Spain; n=718) participated in brief online surveys in 2005 and 2006. Results. US psychiatrists were more likely than EU psychiatrists surveyed to view metabolic syndrome as a significant health risk; US respondents reported significantly more bipolar patients who were overweight or obese, but similar percentages of bipolar patients who met criteria for the metabolic syndrome. More US than EU psychiatrists reported monitoring metabolic parameters before and during treatment, and generally were more concerned about bipolar medication adverse effects (AEs). Significantly more US psychiatrists indicated that they were extremely or very concerned about weight gain as an AE. Conclusions. For most surveyed US and EU psychiatrists, metabolic health is an important concern in the treatment of bipolar disorder. US psychiatrists reported more often monitoring metabolic parameters and adjusting treatment if abnormalities become evident, but practices are evolving in the US and EU.

KW - Bipolar disorder

KW - Cardiovascular diseases

KW - Metabolic syndrome X

KW - Obesity

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=48249088084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249088084&partnerID=8YFLogxK

U2 - 10.1080/13651500701827671

DO - 10.1080/13651500701827671

M3 - Article

VL - 12

SP - 187

EP - 195

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 3

ER -